Wall Street brokerages forecast that Viewray Inc (NASDAQ:VRAY) will announce $17.52 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Viewray’s earnings, with the lowest sales estimate coming in at $14.24 million and the highest estimate coming in at $20.82 million. Viewray posted sales of $20.66 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.2%. The business is scheduled to announce its next earnings report on Thursday, March 12th.
According to Zacks, analysts expect that Viewray will report full year sales of $89.00 million for the current fiscal year, with estimates ranging from $85.55 million to $92.13 million. For the next financial year, analysts anticipate that the company will post sales of $122.15 million, with estimates ranging from $99.94 million to $136.09 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Viewray.
Viewray (NASDAQ:VRAY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.39) earnings per share.
A number of equities research analysts recently commented on the stock. Piper Jaffray Companies set a $6.00 price target on shares of Viewray and gave the stock a “buy” rating in a report on Tuesday, October 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Viewray in a report on Wednesday, November 13th. Oppenheimer assumed coverage on Viewray in a research report on Tuesday, October 22nd. They issued an “outperform” rating and a $7.00 target price for the company. Jefferies Financial Group decreased their target price on Viewray from $14.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, Mizuho restated a “buy” rating and issued a $9.00 target price on shares of Viewray in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $6.10.
Shares of Viewray stock remained flat at $$4.02 on Monday. 3,495,292 shares of the stock were exchanged, compared to its average volume of 1,731,216. The business has a 50 day moving average of $2.91 and a 200 day moving average of $5.48. The company has a quick ratio of 2.58, a current ratio of 3.70 and a debt-to-equity ratio of 0.62. Viewray has a 1 year low of $2.12 and a 1 year high of $9.76. The stock has a market cap of $399.61 million, a price-to-earnings ratio of -4.10 and a beta of 1.09.
Several hedge funds have recently made changes to their positions in VRAY. Quantitative Systematic Strategies LLC bought a new position in Viewray in the 2nd quarter worth approximately $156,000. Wrapmanager Inc. grew its stake in Viewray by 5.5% in the 2nd quarter. Wrapmanager Inc. now owns 34,699 shares of the company’s stock valued at $306,000 after buying an additional 1,797 shares in the last quarter. Stephens Inc. AR grew its stake in Viewray by 9.6% in the 2nd quarter. Stephens Inc. AR now owns 17,420 shares of the company’s stock valued at $153,000 after buying an additional 1,522 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in Viewray by 224.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 41,009 shares of the company’s stock valued at $361,000 after acquiring an additional 28,380 shares during the period. Finally, Swiss National Bank raised its holdings in Viewray by 11.5% during the 2nd quarter. Swiss National Bank now owns 106,900 shares of the company’s stock valued at $942,000 after acquiring an additional 11,000 shares during the period.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Further Reading: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.